Topical rapamycin in facial angiofibroma
Phase 4
- Conditions
- Health Condition 1: Q851- Tuberous sclerosis
- Registration Number
- CTRI/2019/08/020503
- Lead Sponsor
- MGM Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients of facial angiofibroma
Exclusion Criteria
Pregnancy, severe illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rapamycin (sirolimus) is a lipophilic macrocyclic lactone. It is used after renal transplantation and is routinely incorporated in drug-eluting stents during cardiac angioplasty. Rapamycin is very poorly water soluble, severely limiting its bioavailability. Currently it is available in the market in two formulations: Rapamycin oral solution and Rapamycin tablet. Effectiveness is measured by Facial Angiofibroma Severity Index (FASI).Timepoint: Patients will be followed up every 2 weeks and investigations will be done every month.
- Secondary Outcome Measures
Name Time Method There may be treatment related complications e.g erythema, itching, irritation.Timepoint: Topical rapamycin will be discontinued and patient will be started on topical steroid till resolution of complications.